Table 2.

Overview of upadacitinib rheumatoid arthritis phase III program.

Study	SELECT-Early	SELECT-Monotherapy	SELECT-Compare	SELECT- Next	SELECT- Beyond	SELECT-Choice
Population	MTX-naïve	MTX-IR	MTX-IR	csDMARD-IR	bDMARD-IR	bDMARD-IR
Type of therapy	Mono	Mono	Combo	Combo	Combo	Combo
Concomitant background	–	–	MTX	csDMARDs	csDMARDs	csDMARDs
Active comparator	MTX	MTX	ADA	–	–	ABT
Arms	UPA 15 mg QD UPA 30 mg QD MTX	UPA 15 mg QD for 240 weeks UPA 30 mg QD for 240 weeks MTX for 14 week followed by UPA 15 mg QD for 226 weeks MTX for 14 weeks followed by UPA 30 mg QD for 226 weeks	PBO (0–26 weeks), followed by UPA 15 mg QD (27 weeks– 5 years) ADA EOW for 5 years UPA 15 mg QD for 5 years	UPA 15 mg QD for 272 weeks UPA 30 mg QD for 272 weeks PBO for 12 weeks followed by UPA 15 mg QD for 260 weeks PBO for 12 weeks followed by UPA 30 mg QD for 260 weeks	UPA 15 mg QD for 240 weeks UPA 30 mg QD for 240 weeks PBO for 12 weeks followed by UPA 15 mg QD for 228 weeks PBO for 12 weeks followed by UPA 30 mg QD for 228 weeks	ABT i.v. EOW (0–20 weeks), followed by UPA (24 weeks– 5 years) UPA QD for 24 weeks followed by UPA QD for 5 years
Duration Period 1	12 weeks	14 weeks	26 weeks	12 weeks	12 weeks	24 weeks
Actual enrollment	1002	648	1629	661	499	614

ABT, abatacept; ADA, adalimumab; bDMARD, biologic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; EOW, every other week; IR, insufficient responder; MTX, methotrexate; PBO, placebo; QD, once daily; UPA, upadacitinib. Study details from https://clinicaltrials.gov